Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic …

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience.

The resources on this page are offered by Bristol Myers Squibb to assist U.S. healthcare professionals in caring for patients and conducting research with BMS medicines.

Use our Study Finder to help identify new or currently recruiting Bristol Myers Squibb sponsored studies that are being conducted. Submit your question to our team of medical professionals. Bristol Myers …

From the scientists behind the microscope to the analysts behind the data, everyone at BMS is working to make an impact. And while our work transforms the lives of patients, it also transforms the lives …

Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.

Systems linked to a BMS typically represent 40% of a building's energy usage; if lighting is included, this number approaches to 70%. BMS systems are a critical component to managing energy demand.

Learn more about Bristol Myers Squibb, a global biopharma company dedicated to discover, develop and deliver innovative medicines to patients with serious diseases.

Discover the mission, vision, values and commitment of Bristol Myers Squibb, and our dedication to discovering, developing and delivering innovative medicines.